Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-MESODEC: Atezolizumab and WT1/DC Vaccination + Chemotherapy for First-line Epithelioid Malignant Pleural Mesothelioma
NCT05765084Phase 2Recruiting
- Start
- Feb 2023
- Primary completion
- Oct 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, WT1 dendritic cell vaccine in malignant pleural mesothelioma (MPM). Started Feb 2023; status: recruiting.
02
Drugs
atezolizumabWT1 dendritic cell vaccine
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT05765084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765084.